{"id":33267,"date":"2020-08-12T14:51:12","date_gmt":"2020-08-12T13:51:12","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33267"},"modified":"2021-03-18T12:29:27","modified_gmt":"2021-03-18T12:29:27","slug":"companion-diagnostics-biomarkers-2019-speakers","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/","title":{"rendered":"Companion Diagnostics & Biomarkers 2019 Speakers"},"content":{"rendered":"
\n

\n\tOur
Speakers (A-Z)
\n\t<\/h2>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alexander_Bastian_Incyte_BioTech_Pharma_Summit_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alexander_Bastian_Incyte_BioTech_Pharma_Summit_2-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alexander_Bastian_Incyte_BioTech_Pharma_Summit_2-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alexander_Bastian_Incyte_BioTech_Pharma_Summit_2-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alexander_Bastian_Incyte_BioTech_Pharma_Summit_2-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alexander_Bastian_Incyte_BioTech_Pharma_Summit_2-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alexander_Bastian_Incyte_BioTech_Pharma_Summit_2-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33382″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/alexander-bastian\/alexander_bastian_incyte_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alexander_Bastian_Incyte_BioTech_Pharma_Summit_2.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Alexander_Bastian_Incyte_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alexander_Bastian_Incyte_BioTech_Pharma_Summit_2-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alexander_Bastian_Incyte_BioTech_Pharma_Summit_2-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAlexander Bastian\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President of Market Access at Galapagos NV<\/h5>\n

\n\t\t\t\n\tLeveraging RWE to bring value to payers in personalized medicine\n\t\t\t<\/a>\n\t<\/h3>\n\t

Alexander Bastian is Vice President of Market Access at Galapagos NV, a Belgo-Dutch company that develops therapies with proprietary, novel modes-of-action. Here Alex is leading the build-out of the global value and access function, helping to shape the pipeline of future products, and working with health care stakeholders to ensure that value is captured for patients and society from the medications Galapagos brings to regulatory approval.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alexandre_Passioukov_Pierre_Fabre_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alexandre_Passioukov_Pierre_Fabre_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alexandre_Passioukov_Pierre_Fabre_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alexandre_Passioukov_Pierre_Fabre_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alexandre_Passioukov_Pierre_Fabre_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alexandre_Passioukov_Pierre_Fabre_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alexandre_Passioukov_Pierre_Fabre_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32187″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/probiotics-human-skin-microbiome-speakers\/alexandre-passioukov\/alexandre_passioukov_pierre_fabre_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alexandre_Passioukov_Pierre_Fabre_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Alexandre_Passioukov_Pierre_Fabre_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alexandre_Passioukov_Pierre_Fabre_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Alexandre_Passioukov_Pierre_Fabre_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAlexandre Passioukov\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President Translational Medicine at Pierre Fabre<\/h5>\n

\n\t\t\t\n\tFrom Eligibility to CDx: Developping and Implementing Effective Biomarker Strategies for Immuno-Oncology Trials\n\t\t\t<\/a>\n\t<\/h3>\n\t

Alexandre Passioukov leads translational medicine efforts across oncology, CNS and dermatology therapeutic areas at Pierre-Fabre R&D. Previously, Dr. Passioukov was leading translational medicine programs at Roche (Switzerland) with a special focus on immune-oncology drugs. Prior to joining Roche, Alexandre served as Head of Translational Research at EORTC in Brussels, conducting structural translational medicine activities of European clinical research networks.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33363″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/carla-leibowitz_arterys_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tCarla Leibowitz\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Global head of healthcare partnerships at NVIDIA<\/h5>\n

\n\t\t\t\n\tImage-based CDx solutions\n\t\t\t<\/a>\n\t<\/h3>\n\t

Carla Leibowitz is a growth and innovation executive currently leading Corporate Development Arterys, the first company to achieve FDA clearances for several products and a platform that combine cloud computing and artificial intelligence in the medical imaging space. In her role, Carla oversees corporate strategy and planning, business development, geographic expansion and investor relations.<\/p>\n\t\t\t\t\t\t\t\"\"\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christa_Noehammer_Austrian_Institute_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christa_Noehammer_Austrian_Institute_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christa_Noehammer_Austrian_Institute_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christa_Noehammer_Austrian_Institute_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christa_Noehammer_Austrian_Institute_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christa_Noehammer_Austrian_Institute_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christa_Noehammer_Austrian_Institute_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33309″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/christa-noehammer\/christa_noehammer_austrian_institute_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christa_Noehammer_Austrian_Institute_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"4","credit":"","camera":"NIKON D750","caption":"","created_timestamp":"1489749582","copyright":"","focal_length":"120","iso":"0","shutter_speed":"0.005","title":"","orientation":"1"}” data-image-title=”Christa_Noehammer_Austrian_Institute_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christa_Noehammer_Austrian_Institute_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christa_Noehammer_Austrian_Institute_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tChrista Noehammer\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Senior Scientist at the Austrian Institute of Technology<\/h5>\n

\n\t\t\t\n\tExosome-derived epigenetic biomarkers for saliva diagnostics\n\t\t\t<\/a>\n\t<\/h3>\n\t

Christa Noehammer currently works as Senior Scientist at the Austrian Institute of Technology where she has been heading the Molecular Medicine research unit for several years. Holding a master degree in Microbiology and a PhD in Biochemistry she has been working in the microarray field since 1999 being involved in the design, production and data analysis of various microarray types thereby mainly focusing on minimally invasive biomarker discovery for cancer diagnostics.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christophe_Le_Tourneau_Marie_Curie_BioTech_Pharma_Summit_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christophe_Le_Tourneau_Marie_Curie_BioTech_Pharma_Summit_2-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christophe_Le_Tourneau_Marie_Curie_BioTech_Pharma_Summit_2-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christophe_Le_Tourneau_Marie_Curie_BioTech_Pharma_Summit_2-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christophe_Le_Tourneau_Marie_Curie_BioTech_Pharma_Summit_2-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christophe_Le_Tourneau_Marie_Curie_BioTech_Pharma_Summit_2-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christophe_Le_Tourneau_Marie_Curie_BioTech_Pharma_Summit_2-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33401″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/christophe-le-tourneau\/christophe_le_tourneau_marie_curie_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christophe_Le_Tourneau_Marie_Curie_BioTech_Pharma_Summit_2.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Christophe_Le_Tourneau_Marie_Curie_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christophe_Le_Tourneau_Marie_Curie_BioTech_Pharma_Summit_2-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christophe_Le_Tourneau_Marie_Curie_BioTech_Pharma_Summit_2-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tChristophe Le Tourneau\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Senior Medical Oncologist & Professor of Medicine at Institut Curie & Versailles-Saint-Quentin-en-Yvelines University<\/h5>\n

\n\t\t\t\n\tShould every cancer patient be sequenced?\n\t\t\t<\/a>\n\t<\/h3>\n\t

Christophe Le Tourneau is senior Medical Oncologist at the Institut Curie and Professor of Medicine at the Versailles-Saint-Quentin-en-Yvelines University. He is heading the Department of Drug Development and Innovation as well as the Head and Neck Clinic. Christophe Le Tourneau was certified in Medical Oncology in 2005 and got his PhD in Clinical Epidemiology in 2007.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/David_Henderson_Mironid_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/David_Henderson_Mironid_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/David_Henderson_Mironid_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/David_Henderson_Mironid_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/David_Henderson_Mironid_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/David_Henderson_Mironid_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/David_Henderson_Mironid_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33357″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/david-henderson\/david_henderson_mironid_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/David_Henderson_Mironid_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"11","credit":"","camera":"Canon EOS 5D Mark III","caption":"","created_timestamp":"1420813738","copyright":"","focal_length":"85","iso":"100","shutter_speed":"0.05","title":"","orientation":"1"}” data-image-title=”David_Henderson_Mironid_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/David_Henderson_Mironid_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/David_Henderson_Mironid_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tDavid Henderson\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Senior Biologist at Mironid<\/h5>\n

\n\t\t\t\n\tThe discovery and description PDE4D7 as a new prognostic biomarker for advancing prostate cancer\n\t\t\t<\/a>\n\t<\/h3>\n\t

David Henderson is responsible for the efficient and effective delivery of lab based and collaborative research programs covering novel compound development, biomarker discovery and target validation.  Prior to taking up this position with Mironid, David won a prestigious Innovation Fellowship at the Salk Institute for biological studies, San Diego, for his work in epigenetic dysregulation in precancerous disease.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dolores_Cahill_University_Dublin_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dolores_Cahill_University_Dublin_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dolores_Cahill_University_Dublin_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dolores_Cahill_University_Dublin_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dolores_Cahill_University_Dublin_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dolores_Cahill_University_Dublin_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dolores_Cahill_University_Dublin_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33297″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/dolores-cahill\/dolores_cahill_university_dublin_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dolores_Cahill_University_Dublin_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Dolores_Cahill_University_Dublin_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dolores_Cahill_University_Dublin_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Dolores_Cahill_University_Dublin_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tDolores J. Cahill\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Professor of Translational Science at UCD School of Medicine, University College Dublin<\/h5>\n

\n\t\t\t\n\tRecent Developments in Companion Diagnostics in Auto-immune Disease and Immunooncology\n\t\t\t<\/a>\n\t<\/h3>\n\t

Prof. Dr Dolores Cahill has over 25 years expertise in high-throughput protein array, antibody array, proteomics technology development, automation and their biomedical applications, including in biomarker discovery, diagnostics and personalised medicine. She is Professor of Translational Science, School of Medicine and at the Conway Institute at the University College Dublin (UCD) (2005-present).<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gary_Pestano_Biodesix_BioTech_Pharma_summit_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gary_Pestano_Biodesix_BioTech_Pharma_summit_2-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gary_Pestano_Biodesix_BioTech_Pharma_summit_2-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gary_Pestano_Biodesix_BioTech_Pharma_summit_2-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gary_Pestano_Biodesix_BioTech_Pharma_summit_2-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gary_Pestano_Biodesix_BioTech_Pharma_summit_2-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gary_Pestano_Biodesix_BioTech_Pharma_summit_2-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33394″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/gary-pestano\/gary_pestano_biodesix_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gary_Pestano_Biodesix_BioTech_Pharma_summit_2.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Gary_Pestano_Biodesix_BioTech_Pharma_summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gary_Pestano_Biodesix_BioTech_Pharma_summit_2-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gary_Pestano_Biodesix_BioTech_Pharma_summit_2-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tGary Pestano\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President, Development and Operations at Biodesix, Inc.<\/h5>\n

\n\t\t\t\n\tDevelopment and Commercialization of Biomarker Assays for Therapeutic and Diagnostic Guidance in NSCLC\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Gary Pestano leads the Development and Operations departments at Biodesix, a molecular diagnostics company. He is the New York State Clinical Laboratory Evaluation Program (CLEP) Laboratory Director in Boulder, CO of the company\u2019s CLIA, CAP, CLEP, and ISO 13485 -certified laboratory.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/James_Godsey_BioTech_Pharma_Summit_Thermo_Fisher_Scientific_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/James_Godsey_BioTech_Pharma_Summit_Thermo_Fisher_Scientific_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/James_Godsey_BioTech_Pharma_Summit_Thermo_Fisher_Scientific_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/James_Godsey_BioTech_Pharma_Summit_Thermo_Fisher_Scientific_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/James_Godsey_BioTech_Pharma_Summit_Thermo_Fisher_Scientific_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/James_Godsey_BioTech_Pharma_Summit_Thermo_Fisher_Scientific_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/James_Godsey_BioTech_Pharma_Summit_Thermo_Fisher_Scientific_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33338″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/james-godsey\/james_godsey_biotech_pharma_summit_thermo_fisher_scientific_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/James_Godsey_BioTech_Pharma_Summit_Thermo_Fisher_Scientific_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”James_Godsey_BioTech_Pharma_Summit_Thermo_Fisher_Scientific_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/James_Godsey_BioTech_Pharma_Summit_Thermo_Fisher_Scientific_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/James_Godsey_BioTech_Pharma_Summit_Thermo_Fisher_Scientific_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJames Godsey\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President, R&D, Clinical Sequencing Division at Thermo Fisher Scientific<\/h5>\n

\n\t\t\t\n\tDemocratization and Globalization of Next Generation Sequencing for Companion Diagnostics\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. James Godsey has an extensive background (30+ years) in Technology Discovery, Product Development and general management in the infectious disease and cancer diagnostic industry.  He joined Thermo Fisher Scientific in 2015 as the Clinical Sequencing Division was established.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jane_Wilkinson_Broad_Institute_BioTech_Pharma_Summit_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jane_Wilkinson_Broad_Institute_BioTech_Pharma_Summit_2-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jane_Wilkinson_Broad_Institute_BioTech_Pharma_Summit_2-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jane_Wilkinson_Broad_Institute_BioTech_Pharma_Summit_2-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jane_Wilkinson_Broad_Institute_BioTech_Pharma_Summit_2-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jane_Wilkinson_Broad_Institute_BioTech_Pharma_Summit_2-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jane_Wilkinson_Broad_Institute_BioTech_Pharma_Summit_2-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33275″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/jane-wilkinson\/jane_wilkinson_broad_institute_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jane_Wilkinson_Broad_Institute_BioTech_Pharma_Summit_2.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Jane_Wilkinson_Broad_Institute_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jane_Wilkinson_Broad_Institute_BioTech_Pharma_Summit_2-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jane_Wilkinson_Broad_Institute_BioTech_Pharma_Summit_2-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJane Wilkinson\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Senior Director, Genomics Platform Project & Alliance Management at Broad Institute<\/h5>\n

\n\t\t\t\n\tGenomics challenges from a single sample to large clinical studies\n\t\t\t<\/a>\n\t<\/h3>\n\t

Jane Wilkinson is a Senior Director at the Broad Institute where she leads the Broad Genomics Alliance Management team. In this role, Jane manages the platform\u2019s external collaborations and alliances, overseeing the successful implementation and execution. She also works to ensure that the platform meets complex goals from a variety of scientific project types with specific deliverables and deadlines of partnerships, as well as serving as an advocate for those partnerships.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/joana_brilhante_Aipes_Photo_BioTech_Pharma_summit_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/joana_brilhante_Aipes_Photo_BioTech_Pharma_summit_2-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/joana_brilhante_Aipes_Photo_BioTech_Pharma_summit_2-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/joana_brilhante_Aipes_Photo_BioTech_Pharma_summit_2-768×1146.png 768w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33374″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/joana-brilhante\/joana_brilhante_aipes_photo_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/joana_brilhante_Aipes_Photo_BioTech_Pharma_summit_2.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”joana_brilhante_Aipes_Photo_BioTech_Pharma_summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/joana_brilhante_Aipes_Photo_BioTech_Pharma_summit_2-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/joana_brilhante_Aipes_Photo_BioTech_Pharma_summit_2-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJoana Brilhante\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Head of Clinical Development at AIPES<\/h5>\n

\n\t\t\t\n\tNuclear Medicine Imaging for Diagnosing Cancer\n\t\t\t<\/a>\n\t<\/h3>\n\t

Joana has a background in Nuclear Medicine imaging and a Masters of Science in Clinical Research. She worked in the clinic environment and has directed her career towards industry, working in the management of imaging operation in multicenter clinical trials. She has also been involved in the development of diagnostic and therapy novel PET tracers in EU and US markets.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joanne_Hackett_Genomics_England_Biotech_Pharma_summit_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joanne_Hackett_Genomics_England_Biotech_Pharma_summit_2-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joanne_Hackett_Genomics_England_Biotech_Pharma_summit_2-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joanne_Hackett_Genomics_England_Biotech_Pharma_summit_2-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joanne_Hackett_Genomics_England_Biotech_Pharma_summit_2-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joanne_Hackett_Genomics_England_Biotech_Pharma_summit_2-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joanne_Hackett_Genomics_England_Biotech_Pharma_summit_2-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33290″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/joanne-hackett\/joanne_hackett_genomics_england_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joanne_Hackett_Genomics_England_Biotech_Pharma_summit_2.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Joanne_Hackett_Genomics_England_Biotech_Pharma_summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joanne_Hackett_Genomics_England_Biotech_Pharma_summit_2-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joanne_Hackett_Genomics_England_Biotech_Pharma_summit_2-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJoanne Hackett\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Chief Commercial Officer at Genomics England<\/h5>\n

\n\t\t\t\n\tBringing cancer genomics into the clinic\n\t\t\t<\/a>\n\t<\/h3>\n\t

Professor Joanne Hackett is the Chief Commercial Officer at Genomics England and lead member of the Business and Investment Committee.<\/p>\n

As CCO, Joanne is responsible for Genomics England\u2019s industry engagement strategy by developing, managing and accelerating relationships with commercial organisations \u2212 creating opportunities for collaboration both nationally and globally.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Quackenbush_Harvard_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Quackenbush_Harvard_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Quackenbush_Harvard_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Quackenbush_Harvard_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Quackenbush_Harvard_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Quackenbush_Harvard_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Quackenbush_Harvard_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33332″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/john-quackenbush\/john_quackenbush_harvard_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Quackenbush_Harvard_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”John_Quackenbush_Harvard_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Quackenbush_Harvard_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/John_Quackenbush_Harvard_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJohn Quackenbush\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Chair of the Department of Biostatistics at the Harvard School of Public Health<\/h5>\n

\n\t\t\t\n\tMapping cancer risk SNPs to eQTL networks\n\t\t\t<\/a>\n\t<\/h3>\n\t

John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard TH Chan School of Public Health and Professor of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Engelbergs_Jorg_BioTech_Pharma_Summit_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Engelbergs_Jorg_BioTech_Pharma_Summit_2-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Engelbergs_Jorg_BioTech_Pharma_Summit_2-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Engelbergs_Jorg_BioTech_Pharma_Summit_2-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Engelbergs_Jorg_BioTech_Pharma_Summit_2-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Engelbergs_Jorg_BioTech_Pharma_Summit_2-420×627.png 420w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33282″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/jorg-engelbergs\/engelbergs_jorg_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Engelbergs_Jorg_BioTech_Pharma_Summit_2.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Engelbergs_Jorg_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Engelbergs_Jorg_BioTech_Pharma_Summit_2-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Engelbergs_Jorg_BioTech_Pharma_Summit_2-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJ\u00f6rg Engelbergs\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Scientific Regulatory Expert Biomedicines at Paul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines<\/h5>\n

\n\t\t\t\n\tScientific-Regulatory Challenges for Co-Development of Drug and Companion Diagnostics in Europe\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. J\u00f6rg Engelbergs is currently working for the Paul-Ehrlich-Institut in Langen, Germany, as regulatory-scientific expert and assessor (Quality \/ CMC and Non-Clinic) for biopharmaceuticals with focus on Biotechs (Monoclonal Antibodies) and further as expert for IVDs \/ biomarker based Companion Diagnostics (CDx) and stratified \/ personalized (Bio-) Medicines.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lauren_Leiman_Bloodpac_Biotech_Pharma_summit_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lauren_Leiman_Bloodpac_Biotech_Pharma_summit_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lauren_Leiman_Bloodpac_Biotech_Pharma_summit_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lauren_Leiman_Bloodpac_Biotech_Pharma_summit_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lauren_Leiman_Bloodpac_Biotech_Pharma_summit_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lauren_Leiman_Bloodpac_Biotech_Pharma_summit_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lauren_Leiman_Bloodpac_Biotech_Pharma_summit_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33388″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/lauren-leiman\/lauren_leiman_bloodpac_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lauren_Leiman_Bloodpac_Biotech_Pharma_summit_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Lauren_Leiman_Bloodpac_Biotech_Pharma_summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lauren_Leiman_Bloodpac_Biotech_Pharma_summit_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lauren_Leiman_Bloodpac_Biotech_Pharma_summit_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tLauren C. Leiman\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Executive Director at BloodPAC<\/h5>\n

\n\t\t\t\n\tAccelerating Development of Liquid Biopsy technology\n\t\t\t<\/a>\n\t<\/h3>\n\t

Lauren Leiman is currently the Executive Director of the Blood Profiling Atlas in Cancer (BloodPAC), a consortium focused on creating an open database for liquid biopsies to accelerate the development of safe and effective blood profiling diagnostic technologies for patient benefit. Prior to running BloodPAC, she was the Senior Director of External Partnerships at White House Cancer Moonshot Task Force during the Obama Administration.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lisa_Mansell_Abingdon_Health_Profile_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lisa_Mansell_Abingdon_Health_Profile_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lisa_Mansell_Abingdon_Health_Profile_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lisa_Mansell_Abingdon_Health_Profile_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lisa_Mansell_Abingdon_Health_Profile_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lisa_Mansell_Abingdon_Health_Profile_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lisa_Mansell_Abingdon_Health_Profile_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33350″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/lisa-mansell\/lisa_mansell_abingdon_health_profile_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lisa_Mansell_Abingdon_Health_Profile_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"2.2","credit":"","camera":"iPhone 6","caption":"","created_timestamp":"1548141701","copyright":"","focal_length":"4.15","iso":"1000","shutter_speed":"0.058823529411765","title":"","orientation":"1"}” data-image-title=”Lisa_Mansell_Abingdon_Health_Profile_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lisa_Mansell_Abingdon_Health_Profile_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lisa_Mansell_Abingdon_Health_Profile_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tLisa Mansell\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Business Development Manager at Abingdon Health<\/h5>\n

\n\t\t\t\n\tCapabilities in rapid lateral flow technology for companion and complementary diagnostics \u2013 Seralite-FLC case study\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr Lisa Mansell has 18 years of experience in the diagnostic industry including rapid lateral flow diagnostics, ELISA assays, and mass spectrometry methods. Lisa has a degree in Biomedical Science and a PhD in Forensic Toxicology. As Business Development Manager for Abingdon Health\u2019s contract services business she is responsible for managing new lateral flow diagnostic development and manufacturing opportunities.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ron_van_Schaik_ERASMUSMC_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ron_van_Schaik_ERASMUSMC_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ron_van_Schaik_ERASMUSMC_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ron_van_Schaik_ERASMUSMC_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ron_van_Schaik_ERASMUSMC_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ron_van_Schaik_ERASMUSMC_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ron_van_Schaik_ERASMUSMC_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33319″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/ron-van-schaik\/ron_van_schaik_erasmusmc_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ron_van_Schaik_ERASMUSMC_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"2.8","credit":"","camera":"Canon EOS 5D Mark III","caption":"","created_timestamp":"1526390432","copyright":"","focal_length":"63","iso":"160","shutter_speed":"0.005","title":"","orientation":"1"}” data-image-title=”Ron_van_Schaik_ERASMUSMC_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ron_van_Schaik_ERASMUSMC_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ron_van_Schaik_ERASMUSMC_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tRon van Schaik\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Professor Pharmacogenetics Erasmus MC; President European Society for Pharmacogenomics & Personalised Therapy (ESPT)<\/h5>\n

\n\t\t\t\n\tUsing the best practices for Biobanking\n\t\t\t<\/a>\n\t<\/h3>\n\t

Prof. Dr. Ron van Schaik (PhD, FACB) is a registered European Specialist Laboratory Medicine and a Full Professor of Pharmacogenetics. He is working at the Dept. Clinical Chemistry at the Erasmus University Medical Center Rotterdam, and is Director of the International (IFCC) Expert-center for Pharmacogenetics. Main interest is the clinical implementation of pharmacogenetics and pharmacogenetics translational research.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Simon_Patton_Manchester_University_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Simon_Patton_Manchester_University_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Simon_Patton_Manchester_University_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Simon_Patton_Manchester_University_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Simon_Patton_Manchester_University_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Simon_Patton_Manchester_University_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Simon_Patton_Manchester_University_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33368″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/simon-patton\/simon_patton_manchester_university_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Simon_Patton_Manchester_University_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Simon_Patton_Manchester_University_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Simon_Patton_Manchester_University_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Simon_Patton_Manchester_University_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tSimon Patton\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director at European Molecular Genetics Quality Network (EMQN)<\/h5>\n

\n\t\t\t\n\tA global perspective on BRCA gene testing: a new paradigm for molecular testing in breast and ovarian cancer\n\t\t\t<\/a>\n\t<\/h3>\n\t

Simon Patton, PhD is currently Director of the European Molecular Genetics Quality Network (EMQN) \u2013 the global leader in the provision of External Quality Assessment (EQA) schemes to diagnostic laboratories in the fields of genetics and pathology. He trained at the University of Liverpool in marine biology, before doing his doctorate in Genetics at the University of Cambridge. He is currently at Manchester University NHS Foundation Trust.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Stefan_Kostense_Janssen_BioTech_Pharma_Summit_profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Stefan_Kostense_Janssen_BioTech_Pharma_Summit_profile_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Stefan_Kostense_Janssen_BioTech_Pharma_Summit_profile_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Stefan_Kostense_Janssen_BioTech_Pharma_Summit_profile_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Stefan_Kostense_Janssen_BioTech_Pharma_Summit_profile_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Stefan_Kostense_Janssen_BioTech_Pharma_Summit_profile_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Stefan_Kostense_Janssen_BioTech_Pharma_Summit_profile_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33325″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/stefan-kostense\/stefan_kostense_janssen_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Stefan_Kostense_Janssen_BioTech_Pharma_Summit_profile_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"4","credit":"","camera":"Canon EOS 5D Mark III","caption":"","created_timestamp":"1463442799","copyright":"","focal_length":"115","iso":"125","shutter_speed":"0.008","title":"","orientation":"1"}” data-image-title=”Stefan_Kostense_Janssen_BioTech_Pharma_Summit_profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Stefan_Kostense_Janssen_BioTech_Pharma_Summit_profile_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Stefan_Kostense_Janssen_BioTech_Pharma_Summit_profile_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tStefan Kostense\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director, Biomarkers, Janssen (Johnson & Johnson).<\/h5>\n

\n\t\t\t\n\tBiomarkers predicting the development of Alzheimer\u2019s Disease\n\t\t\t<\/a>\n\t<\/h3>\n\t

After obtaining his PhD on HIV specific immunity, he joined Crucell\/Janssen as a scientist, evaluating vaccine immunogenicity in preclinical models. He has set up up the Clinical Immunology department of 35 FTE, and set up a GLP and GCLP compliant laboratory including LIMS, for the analysis of toxicity and clinical samples, supporting the development of antibody therapeutics and vaccines. As department head he was responsible for the scientific strategy, operational efficiency, and effective outsourcing to CRO\u2019s or collaboration with external key opinion leaders.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tuc_Ahmad_covance_biotech_pharma_summit_profile_2-copy.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tuc_Ahmad_covance_biotech_pharma_summit_profile_2-copy-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tuc_Ahmad_covance_biotech_pharma_summit_profile_2-copy-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tuc_Ahmad_covance_biotech_pharma_summit_profile_2-copy-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tuc_Ahmad_covance_biotech_pharma_summit_profile_2-copy-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tuc_Ahmad_covance_biotech_pharma_summit_profile_2-copy-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tuc_Ahmad_covance_biotech_pharma_summit_profile_2-copy-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33344″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/tuc-ahmad\/tuc_ahmad_covance_biotech_pharma_summit_profile_2-copy\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tuc_Ahmad_covance_biotech_pharma_summit_profile_2-copy.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Tuc_Ahmad_covance_biotech_pharma_summit_profile_2 copy” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tuc_Ahmad_covance_biotech_pharma_summit_profile_2-copy-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tuc_Ahmad_covance_biotech_pharma_summit_profile_2-copy-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tTuc Ahmad\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Scientific Director at Covance<\/h5>\n

\n\t\t\t\n\tThe Role of Effective Partnerships in Delivering a Biomarker\/Companion Diagnostic Strategy\n\t\t\t<\/a>\n\t<\/h3>\n\t

Tuc is Scientific Director in the Covance Diagnostic Development team and based in Europe.  He has responsibility as the primary scientific contact for Biopharma clients for initial engagement on new biomarker programs focused on discovery to provide a better understanding of therapeutic targets, molecular signaling, drug biology and patient response.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33304″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/yong-jie-lu\/yong-jie_lu_biotech_pharma_summit_university_london_molecular_oncology_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"DMC-G3","caption":"","created_timestamp":"1431439568","copyright":"","focal_length":"0","iso":"800","shutter_speed":"0.002","title":"","orientation":"1"}” data-image-title=”Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Yong-Jie_Lu_BioTech_Pharma_Summit_University_London_Molecular_Oncology_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tYong-Jie Lu\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Professor in Molecular Oncology at Barts Cancer Institute, Queen Mary University of London<\/h5>\n

\n\t\t\t\n\tLiquid biopsy- the future of cancer diagnosis and precision medicine\n\t\t\t<\/a>\n\t<\/h3>\n\t

Professor Yong-Jie Lu is a professor in Molecular Oncology at Barts Cancer Institute, The Barts and London School of Medicine and Dentistry, Queen Mary University of London. He completed his medical training in 1989 at Medical College, Zhengzhou University, then MD in 1992 at Harbin Medical University and PhD in 1995 at Cancer Institute\/Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC).<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Our Speakers (A-Z) Alexandre Passioukov Vice President Translational Medicine at Pierre Fabre From Eligibility to CDx: Developping and Implementing Effective Biomarker Strategies for Immuno-Oncology Trials Alexandre Passioukov leads translational medicine efforts across oncology, CNS and dermatology therapeutic areas at Pierre-Fabre R&D. Previously, Dr. Passioukov was leading translational medicine programs at Roche (Switzerland) with a special…<\/p>\n","protected":false},"author":1,"featured_media":31740,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-33267","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nCompanion Diagnostics & Biomarkers 2019 Speakers • BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"The BioTech Pharma Summit is proud to present the 2nd Annual Companion Diagnostics & Biomarkers 2019. This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Companion Diagnostics & Biomarkers 2019 Speakers • BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"The BioTech Pharma Summit is proud to present the 2nd Annual Companion Diagnostics & Biomarkers 2019. This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-18T12:29:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_CDx_Biomakers_Website_Final.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1152\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/\",\"name\":\"Companion Diagnostics & Biomarkers 2019 Speakers • BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_CDx_Biomakers_Website_Final.png\",\"datePublished\":\"2020-08-12T13:51:12+00:00\",\"dateModified\":\"2021-03-18T12:29:27+00:00\",\"description\":\"The BioTech Pharma Summit is proud to present the 2nd Annual Companion Diagnostics & Biomarkers 2019. This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_CDx_Biomakers_Website_Final.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_CDx_Biomakers_Website_Final.png\",\"width\":1920,\"height\":1152},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Companion Diagnostics & Biomarkers 2019 Speakers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow's healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Companion Diagnostics & Biomarkers 2019 Speakers • BioTech Pharma Summit","description":"The BioTech Pharma Summit is proud to present the 2nd Annual Companion Diagnostics & Biomarkers 2019. This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/","og_locale":"en_US","og_type":"article","og_title":"Companion Diagnostics & Biomarkers 2019 Speakers • BioTech Pharma Summit","og_description":"The BioTech Pharma Summit is proud to present the 2nd Annual Companion Diagnostics & Biomarkers 2019. This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-18T12:29:27+00:00","og_image":[{"width":1920,"height":1152,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_CDx_Biomakers_Website_Final.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/","name":"Companion Diagnostics & Biomarkers 2019 Speakers • BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_CDx_Biomakers_Website_Final.png","datePublished":"2020-08-12T13:51:12+00:00","dateModified":"2021-03-18T12:29:27+00:00","description":"The BioTech Pharma Summit is proud to present the 2nd Annual Companion Diagnostics & Biomarkers 2019. This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_CDx_Biomakers_Website_Final.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_CDx_Biomakers_Website_Final.png","width":1920,"height":1152},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Companion Diagnostics & Biomarkers 2019 Speakers"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow's healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=33267"}],"version-history":[{"count":4,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33267\/revisions"}],"predecessor-version":[{"id":36073,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33267\/revisions\/36073"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/31740"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=33267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}